172 related articles for article (PubMed ID: 17692685)
41. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.
Mohsin N; Budruddin M; Pakkyara A; Darweesh A; Nayyer M; Amitabh J; Daar AS
Exp Clin Transplant; 2005 Dec; 3(2):366-9. PubMed ID: 16417445
[TBL] [Abstract][Full Text] [Related]
42. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
Yilmaz R; Akoglu H; Kirkpantur A; Kilickap S; Arici M; Altun B; Aki T; Erdem Y; Yasavul U; Turgan C
Ren Fail; 2007; 29(1):103-5. PubMed ID: 17365918
[TBL] [Abstract][Full Text] [Related]
43. Development of malignancy following living donor kidney transplantation.
Nafar M; Einollahi B; Hemati K; Gholi FP; Firouzan A
Transplant Proc; 2005 Sep; 37(7):3065-7. PubMed ID: 16213306
[TBL] [Abstract][Full Text] [Related]
44. Kaposi sarcoma in solid organ transplant recipients: a single center report.
Boeckle E; Boesmueller C; Wiesmayr S; Mark W; Rieger M; Tabarelli D; Graziadei I; Hoefer D; Antretter H; Stelzmueller I; Krugmann J; Zangerle R; Huemer H; Poelzl G; Margreiter R; Bonatti H
Transplant Proc; 2005 May; 37(4):1905-9. PubMed ID: 15919500
[TBL] [Abstract][Full Text] [Related]
45. Minimizing the risk of posttransplant malignancy.
Campistol JM
Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
[TBL] [Abstract][Full Text] [Related]
46. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
Clin Transplant; 2008; 22(5):645-50. PubMed ID: 18657156
[TBL] [Abstract][Full Text] [Related]
47. Urological malignancy after renal transplantation.
Besarani D; Cranston D
BJU Int; 2007 Sep; 100(3):502-5. PubMed ID: 17669141
[TBL] [Abstract][Full Text] [Related]
48. Characteristics of neoplasm occurrence and the therapeutic effect of sirolimus in South Chinese kidney transplant recipients.
Wang CX; Liu LS; Chen LZ; Chen SY; Wu PG; Fei JG; Qiu J; Deng SX; Zheng KL; Ji YL; Zhu LY; Shen QR; He XS
Transplant Proc; 2006 Dec; 38(10):3536-9. PubMed ID: 17175325
[TBL] [Abstract][Full Text] [Related]
49. Early de novo malignancies after kidney transplantation.
Veroux M; Puliatti C; Fiamingo P; Cappello D; Macarone M; Puliatti D; Vizcarra D; Gagliano M; Veroux P
Transplant Proc; 2004 Apr; 36(3):718-20. PubMed ID: 15110643
[TBL] [Abstract][Full Text] [Related]
50. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
[TBL] [Abstract][Full Text] [Related]
51. [A case of Kaposi's sarcoma in the rapamycin era].
Gemelli A; Paciolla A; Oliosi F; Basso A; Moscardin R; Tineo MC; Romano P; Alaibac M; Aversa S; Furian L; D'Angelo A; Bonfante L
G Ital Nefrol; 2009; 26(1):90-3. PubMed ID: 19255968
[TBL] [Abstract][Full Text] [Related]
52. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
[TBL] [Abstract][Full Text] [Related]
53. Sirolimus in renal transplantation.
Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
[TBL] [Abstract][Full Text] [Related]
54. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
Oberbauer R
Transplantation; 2009 Apr; 87(8 Suppl):S7-10. PubMed ID: 19384186
[TBL] [Abstract][Full Text] [Related]
55. Rapamycin in lung transplantation.
Hernández RL; Gil PU; Gallo CG; de Pablo Gafas A; Hernández MC; Alvarez MJ
Transplant Proc; 2005 Nov; 37(9):3999-4000. PubMed ID: 16386609
[TBL] [Abstract][Full Text] [Related]
56. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
57. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
58. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
59. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
Gaumann A; Schlitt HJ; Geissler EK
Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
[TBL] [Abstract][Full Text] [Related]
60. Drug insight: maintenance immunosuppression in kidney transplant recipients.
Samaniego M; Becker BN; Djamali A
Nat Clin Pract Nephrol; 2006 Dec; 2(12):688-99. PubMed ID: 17124526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
